FDA Hosts Workshop to Improve Community Access to Life-Saving Epinephrine
Published Date: 11/24/2025
Notice
Summary
The FDA is hosting a workshop on December 16, 2025, to talk about making epinephrine easier to get for people who might have severe allergic reactions (anaphylaxis). This effort aims to save lives by getting epinephrine into more hands, especially in community places. Everyone can join online or in person and share their thoughts by January 16, 2026, helping shape future access and safety improvements.
Analyzed Economic Effects
6 provisions identified: 0 benefits, 6 costs, 0 mixed.
Many at-risk patients lack or avoid epinephrine
Anaphylaxis can progress within 15 to 30 minutes and epinephrine is the only effective first-line treatment. The document says up to 5 percent lifetime prevalence in the U.S. and about 200 deaths annually, and it notes patients prescribed epinephrine may not have it available during an event or may choose not to use it because of knowledge gaps, fear, stigma, or incorrect use.
Community sites often lack epinephrine policies
Schools, workplaces, restaurants, sports facilities, transportation vehicles, and public venues may lack policies for epinephrine storage, staff training, and emergency administration. That institutional lack of preparedness can reduce access to epinephrine where anaphylaxis commonly happens.
State liability rules discourage stocking epinephrine
State laws vary regarding Good Samaritan protections for lay administration of epinephrine, and these liability concerns can discourage institutions from maintaining emergency epinephrine supplies.
Cost of epinephrine limits community availability
The document identifies economic obstacles from the cost of epinephrine products as a barrier to having community‑use epinephrine available in public settings, which can limit access during emergencies.
Rural disparities reduce timely epinephrine access
The document notes geographic disparities, especially in rural communities where pharmacies may be spread out and emergency medical services can have longer response times, which can limit timely access to epinephrine.
Prescription and provider authorization create access hurdles
The notice identifies procedural barriers such as obtaining healthcare provider authorization and maintaining a current prescription for epinephrine as factors that can limit access to this life‑saving medication.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12445 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Traction Device
The FDA is officially putting the endoscopic traction device into Class II, meaning it now has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while making it easier for patients to get access to this cool medical tool. The new rules took effect on June 22, 2026, and could speed up innovation without extra costs for makers.
2026-12444 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Light-Projecting Measuring Device
The FDA is officially putting the endoscopic light-projecting measuring device into Class II, meaning it now has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while speeding up patient access to cool new tech. The new rules took effect June 22, 2026, and could save time and money for makers and users alike.
2026-12367 — Epizyme, Inc.; Withdrawal of Approval of New Drug Application for TAZVERIK (Tazemetostat) Tablet, 200 Milligrams
Epizyme, Inc. has asked the FDA to withdraw approval for their cancer drug TAZVERIK (200 mg tablets), effective June 22, 2026. This means TAZVERIK will no longer be officially approved for treating certain sarcomas and lymphomas, affecting patients and healthcare providers relying on it. The change might impact treatment options and insurance coverage, so folks should check with their doctors about next steps.
2026-12443 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple In Vitro Diagnostic Device for the Detection of Secreted Proteins From Bacillus Species (spp.) in Human Clinical Samples
The FDA is officially putting a simple test that spots proteins from Bacillus bacteria in human samples into a safer, easier-to-manage category called Class II. This change helps make sure the test is safe and works well while speeding up patient access to cool new medical tools. The new rules kicked in on June 22, 2026, but have been in effect since February 3, 2023, making life simpler for device makers and patients alike.
2026-12245 — Authorization of Emergency Use for Two Animal Drugs for the Prevention and Treatment of New World Screwworm; Availability
The FDA just gave the green light for two new animal drugs to fight the nasty New World screwworm, a bug that harms cattle, horses, pigs, and even exotic animals. These emergency approvals started in April 2026 to help protect U.S. livestock and wildlife quickly. Farmers, vets, and animal lovers can now use these treatments to stop infestations and keep animals safe without delay.
2026-12237 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice Regulations for Type A Medicated Articles and Medicated Feeds
The FDA is updating how companies that make special animal medicines and feeds keep their records and follow quality rules. This affects manufacturers of Type A medicated articles and medicated feeds, helping ensure safe and reliable products for animals. Comments on these changes are open until July 20, 2026, and the updates aim to keep things clear without adding extra costs.
Previous / Next Documents
Previous: 2025-20657 — Carroll County Energy LLC; Notice of Institution of Section 206 Proceeding And Refund Effective Date
The Federal Energy Regulatory Commission is checking if Carroll County Energy LLC’s rates are fair or not. If they find the rates unfair, refunds could start from November 24, 2025. Anyone interested has 21 days to speak up and get involved in the process.
Next: 2025-20659 — Agency Information Collection Activities; Proposed eCollection eComments Requested; DEA Voluntary Wellness Program Healthcare Provider Clearance
The Drug Enforcement Administration (DEA) wants your feedback on a new form for their Voluntary Wellness Program aimed at healthcare providers. They’re asking for comments by December 24, 2025, to make sure the form is easy to use and not too time-consuming. This helps the DEA improve the program without costing extra money or hassle for those involved.